Global Health Limited has informed the Exchange regarding Change in Auditors of the company.
MEDANTA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.4 pts more than Nifty Midcap 150 and 6.8 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Global Health Limited (Medanta) announced its Q1 FY26 results with standalone revenue of Rs. 8,821.56 million (up ~16% YoY on restated basis) and consolidated revenue of Rs. 10,308.37 million. Standalone profit after tax rose to Rs. 1,519.64 million (vs Rs. 1,085.51 million restated), with EPS at Rs. 5.66. The Board set August 22, 2025 as the record date for a final dividend of Rs. 0.50 per share for FY25, subject to shareholder approval at the September 19, 2025 AGM. The Board recommended re-appointment of Dr. Naresh Trehan as CMD for 5 years from August 1, 2026, along with re-appointments of two Independent Directors. Despite the headline referring to a change in auditors, the statutory auditor Walker Chandiok & Co LLP continues; the change is the appointment of MAKS & Co as new Secretarial Auditor for 5 years starting FY26, pending shareholder approval.
Strong Q1 performance with healthy revenue and profit growth supports investor sentiment. Dividend announcement and continuity of key leadership (including founder-promoter Dr. Trehan) provide stability. The secretarial auditor appointment is a routine governance compliance matter and unlikely to affect the stock price.